|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
Epidemiology/Health Services/Psychosocial Research |
Clinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes
A 1-year randomized controlled trial
1 University of Pittsburgh, Pittsburgh, Pennsylvania
2 Pennington Research Center, Baton Rouge, Louisiana
3 Columbia University, New York, New York
4 Washington University, St. Louis, Missouri
5 University of Colorado, Denver, Colorado
6 University of Missouri-Kansas City, Kansas City, Missouri
7 Baylor College of Medicine, Houston, Texas
OBJECTIVE—Weight loss improves glycemic control, lipid profiles, and blood pressure in patients with type 2 diabetes. However, successful long-term weight loss is difficult for these patients, particularly those treated with insulin. The aim of this study was to assess the effect of orlistat, a gastrointestinal lipase inhibitor, on weight loss, glycemic control, and cardiovascular risk factors in overweight or obese insulin-treated type 2 diabetic patients.
RESEARCH DESIGN AND METHODS—This study was a 1-year multicenter, randomized, double-blind, placebo-controlled trial of orlistat (120 mg three times a day) or placebo combined with a reduced-calorie diet in overweight or obese adults (BMI 28–40 kg/m2) with type 2 diabetes treated with insulin alone or combined with oral agents, but with suboptimal metabolic control (HbA1c 7.5–12.0%). Outcome measurements included changes in body weight, glycemic control, blood pressure, and serum lipids.
RESULTS—After 1 year, the orlistat group lost significantly more weight (-3.89 ± 0.3% of baseline body weight, means ± SE) than the placebo group (-1.27 ± 0.3%, P < 0.001). Orlistat treatment, compared with placebo, produced greater decreases in HbA1c (-0.62 ± 0.08 vs. -0.27 ± 0.08%, P = 0.002), fasting serum glucose (-1.63 ± 0.3 vs. -1.08 ± 0.3 mmol/l, P = 0.02), and the required doses of insulin and other diabetic medications. Orlistat also produced greater improvements than placebo in serum total cholesterol (P = 0.0002) and LDL cholesterol concentrations (P = 0.001) and LDL/HDL ratio (P = 0.01).
CONCLUSIONS—Orlistat therapy produces clinically significant weight loss, with improvements in glycemic control and cardiovascular disease risk factors, in overweight or obese patients with type 2 diabetes who have suboptimal metabolic control with insulin therapy.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  K. C. Dunican, A. R. Desilets, and R. J. DeBellis State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant American Journal of Lifestyle Medicine, October 1, 2007; 1(5): 367 - 388. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Aronne, K. Fujioka, V. Aroda, K. Chen, A. Halseth, N. C. Kesty, C. Burns, C. W. Lush, and C. Weyer Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2977 - 2983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hollander Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes Diabetes Spectr, July 1, 2007; 20(3): 159 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Bray and F. L. Greenway Pharmacological Treatment of the Overweight Patient Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184. [Full Text] [PDF]
|
|
|
|
 |
|
 D. C.W. Lau, J. D. Douketis, K. M. Morrison, I. M. Hramiak, A. M. Sharma, E. Ur, and for members of the Obesity Canada Clinical Practic 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary] Can. Med. Assoc. J., April 10, 2007; 176(8): S1 - S13. [Full Text] [PDF]
|
|
|
|
|
|
D. C.W. Lau, J. D. Douketis, K. M. Morrison, I. M. Hramiak, A. M. Sharma, E. Ur, and pour les membres du Groupe d'experts d'Obesite Can Lignes directrices canadiennes de 2006 sur la prise en charge et la prevention de l'obesite chez les adultes et les enfants [sommaire] Can. Med. Assoc. J., April 10, 2007; 176(8): SF1 - SF14. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Carver Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes The Diabetes Educator, November 1, 2006; 32(6): 910 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Gadde and D. B. Allison Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks Circulation, August 29, 2006; 114(9): 974 - 984. [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Redmon, K. P. Reck, S. K. Raatz, J. E. Swanson, C. A. Kwong, H. Ji, W. Thomas, and J. P. Bantle Two-Year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes Diabetes Care, June 1, 2005; 28(6): 1311 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Li, M. Maglione, W. Tu, W. Mojica, D. Arterburn, L. R. Shugarman, L. Hilton, M. Suttorp, V. Solomon, P. G. Shekelle, et al. Meta-Analysis: Pharmacologic Treatment of Obesity Ann Intern Med, April 5, 2005; 142(7): 532 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y.Y. Cheng and I. G. Fantus Oral antihyperglycemic therapy for type 2 diabetes mellitus Can. Med. Assoc. J., January 18, 2005; 172(2): 213 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hutton and D. Fergusson Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1461 - 1468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Klein, L. E. Burke, G. A. Bray, S. Blair, D. B. Allison, X. Pi-Sunyer, Y. Hong, and R. H. Eckel Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease: A Statement for Professionals From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation Circulation, November 2, 2004; 110(18): 2952 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Norris, X. Zhang, A. Avenell, E. Gregg, C. H. Schmid, C. Kim, and J. Lau Efficacy of Pharmacotherapy for Weight Loss in Adults With Type 2 Diabetes Mellitus: A Meta-analysis Arch Intern Med, July 12, 2004; 164(13): 1395 - 1404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Wolf, M. R. Conaway, J. Q. Crowther, K. Y. Hazen, J. L.Nadler, B. Oneida, and V. E. Bovbjerg Translating Lifestyle Intervention to Practice in Obese Patients With Type 2 Diabetes: Improving Control with Activity and Nutrition (ICAN) study Diabetes Care, July 1, 2004; 27(7): 1570 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Kelley, L. H. Kuller, T. M. McKolanis, P. Harper, J. Mancino, and S. Kalhan Effects of Moderate Weight Loss and Orlistat on Insulin Resistance, Regional Adiposity, and Fatty Acids in Type 2 Diabetes Diabetes Care, January 1, 2004; 27(1): 33 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Redmon, S. K. Raatz, K. P. Reck, J. E. Swanson, C. A. Kwong, Q. Fan, W. Thomas, and J. P. Bantle One-Year Outcome of a Combination of Weight Loss Therapies for Subjects With Type 2 Diabetes: A randomized trial Diabetes Care, September 1, 2003; 26(9): 2505 - 2511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pilichiewicz, D. O'Donovan, C. Feinle, Y. Lei, J. M. Wishart, L. Bryant, J. H. Meyer, M. Horowitz, and K. L. Jones Effect of Lipase Inhibition on Gastric Emptying of, and the Glycemic and Incretin Responses to, an Oil/Aqueous Drink in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3829 - 3834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Dawson and C. Conlon Case Study: Metformin-Associated Lactic Acidosis: Could orlistat be relevant? Diabetes Care, August 1, 2003; 26(8): 2471 - 2472. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |